公开(公告)号：US20240342264A1

公开(公告)日：2024-10-17

申请号：US18605229

申请日：2024-03-14

申请人： Ospedale San Raffaele S.r.I. ,  Fondazione Telethon ETS

发明人： Alessio Cantore ,  Angelo Leone Lombardo ,  Luigi Naldini

IPC分类号： A61K39/12 ,  C12N7/04 ,  C12N15/86

CPC分类号： A61K39/12 ,  C12N7/04 ,  C12N15/86 ,  A61K2121/00 ,  C12N2740/10052 ,  C12N2740/16041 ,  C12N2740/16052

摘要： An enveloped viral particle producer or packaging cell, wherein the cell is genetically engineered to decrease expression of MHC-I on the surface of the cell.

公开(公告)号：US20240024459A1

公开(公告)日：2024-01-25

申请号：US18041541

申请日：2021-08-13

申请人： INSTITUTO BUTANTAN

发明人： RICARDO DAS NEVES OLIVEIRA ,  ANA MARISA CHUDZINSKI-TAVASSI ,  DENISE VILARINHO TAMBOURGI ,  VIVIANE FONGARO BOTOSSO ,  SORAIA ATTIE CAUL JORGE ,  RENATO MANCINI ASTRAY ,  MONICA BEATRIZ MATHOR

IPC分类号： A61K39/215 ,  A61K41/17 ,  C12N7/04 ,  A61P31/14 ,  C07K16/10 ,  B01D15/36 ,  B01D61/14

CPC分类号： A61K39/215 ,  A61K41/17 ,  C12N7/04 ,  A61P31/14 ,  C07K16/1003 ,  B01D15/361 ,  B01D61/145 ,  A61K2039/5252

摘要： The present invention relates to techniques and methods for producing, purifying, inactivating and analyzing SARS-CoV-2. The present invention relates to the method for producing an antigen corresponding to the SARS-COV-2 virus inactivated by gamma radiation. The method for producing an antigen corresponding to the SARS-COV-2 virus inactivated by gamma radiation is intended for use in the production of a novel vaccine, the antigen being used in the production of hyperimmune plasma in horses for serum therapy, and in different animal species for the production of antibodies/research inputs and the establishment of serum diagnosis techniques. The present invention relates to the antigenic composition including the antigen corresponding to the inactivated SARS-COV-2 virus and a pharmaceutically acceptable diluent excipient. The invention also relates to a method for producing anti-SARS-CoV-2 immunoglobulins using the SARS-COV-2 virus inactivated by gamma radiation.

公开(公告)号：US20180344837A1

公开(公告)日：2018-12-06

申请号：US15989454

申请日：2018-05-25

申请人： The United States of America, as represented by the Secretary of Agriculture

发明人： Kay S. Faaberg ,  Allyn Spear ,  Matthew A. Kappes ,  Kelly M. Lager

IPC分类号： A61K39/12

CPC分类号： A61K39/12 ,  A61K2039/5254 ,  A61K2039/53 ,  A61K2039/575 ,  A61P31/14 ,  C12N7/04 ,  C12N2770/10021 ,  C12N2770/10034 ,  C12N2770/10062

摘要： Multiple DIVA vaccines effective against porcine reproductive and respiratory syndrome virus (PRRSV) are disclosed. The DIVA vaccines may be negative DIVAs or positive DIVAs. The DIVA vaccines may be produced by modifying the nsp2 region of a modified live virus vaccine. The modification may be one or more deletions only (negative DIVAs) or a deletion with an insertion (positive DIVAs). The insertion may be of an epitope tag, such as a V5, S-Tag, or FLAG tag. Produced DIVA vaccines may be stable through multiple passes and thus may be effective for production and vaccination of animals.

公开(公告)号：US20180255751A1

公开(公告)日：2018-09-13

申请号：US15468652

申请日：2017-03-24

申请人： The Broad Institute Inc. ,  Massachusetts Institute of Technology ,  The General Hospital Corporation

发明人： Aviv Regev ,  Oren PARNAS ,  Marko JOVANOVIC ,  Nir HACOHEN ,  Thomas EISENHAURE

IPC分类号： A01K67/027 ,  C12N15/10 ,  C12N15/85 ,  C12N15/90 ,  C12N9/22 ,  C12N7/04 ,  A61K48/00

CPC分类号： A01K67/0271 ,  A01K67/0275 ,  A01K2207/05 ,  A01K2207/12 ,  A01K2217/052 ,  A01K2217/077 ,  A01K2227/105 ,  A01K2267/0312 ,  A01K2267/0331 ,  A01K2267/0362 ,  A61K48/005 ,  C07K2319/09 ,  C12N7/04 ,  C12N9/22 ,  C12N15/1082 ,  C12N15/111 ,  C12N15/113 ,  C12N15/85 ,  C12N15/907 ,  C12N2310/10 ,  C12N2310/20 ,  C12N2310/3513 ,  C12N2310/531 ,  C12N2320/12 ,  C12N2330/31 ,  C12N2330/51 ,  C12N2740/15043 ,  C12N2750/14143

摘要： The invention involves a method for modulating leukocyte activity, comprising delivering to a leukocyte a vector containing nucleic acid molecule(s), whereby the leukocyte contains Cas9 and the vector expresses one or more RNAs to guide the Cas9 to introduce mutations in one or more target genetic loci in the leukocyte, thereby modulating expression of one or more genes expressed in the leukocyte. The invention also involves identifying genes associated with leukocyte responses and experimental modeling of aberrant leukocyte activation and diseases associated with leukocytes by introducing mutations into leukocytes. The invention comprehends testing putative treatments with such models, e.g., testing putative chemical compounds that may be pharmaceutically relevant for treatment or gene therapy that may be relevant for treatment, or combinations thereof. The invention allows for the study of genetic diseases and putative treatments to better understand and alleviate leukocyte associated diseases.

公开(公告)号：US20180002384A1

公开(公告)日：2018-01-04

申请号：US15533377

申请日：2015-12-08

申请人： LIFE SCIENCE INKUBATOR GMBH

发明人： SEBASTIAN FRANKEN ,  ALEXANDER GLASSMANN ,  NADINE TEMME

IPC分类号： C07K14/01 ,  C12N7/04 ,  C07K2/00

CPC分类号： C07K14/01 ,  C07K2/00 ,  C07K14/005 ,  C07K2319/01 ,  C12N7/04 ,  C12N2710/22022 ,  C12N2710/22023 ,  C12N2710/22042 ,  C12N2810/40

摘要： The disclosure relates to a fusion protein comprising at least a first and a second peptide, wherein —the second peptide comprises a targeting region and a first and a second interaction region, —the second peptide is located on the surface of the fusion protein; —the second peptide comprises at least two interaction pairs, wherein an interaction pair is formed by an amino acid of the first interaction region and an amino acid of the second interaction region, —the interaction between the amino acids of an interaction pair is covalent or non-covalent; and —at least one interaction pair is a covalent interaction pair in which the amino acids are covalently bound, and to virus like particles (VLP) comprising the fusion protein for use as drug delivery system. Also provided are polynucleotides encoding the fusion protein, suitable expression vectors, host cells, production methods for the fusion protein and the VLP comprising the fusion protein.

公开(公告)号：US20170298389A1

公开(公告)日：2017-10-19

申请号：US15517768

申请日：2015-10-09

申请人： Vaxart, Inc.

发明人： Ciaran Scallan ,  Wendy Peters

IPC分类号： C12N15/869 ,  A61K39/245 ,  C07K14/035 ,  C12N15/09 ,  C12N7/04 ,  C07K14/005 ,  A61K39/00 ,  C12N15/00

CPC分类号： C12N15/869 ,  A61K39/00 ,  A61K39/12 ,  A61K39/245 ,  A61K2039/572 ,  C07K14/005 ,  C07K14/035 ,  C12N7/04 ,  C12N15/00 ,  C12N15/09 ,  C12N2710/10043 ,  C12N2710/16034 ,  C12N2710/16622 ,  C12N2710/16643

摘要： Provided herein are improved vaccines for HSV-2.

公开(公告)号：US09630996B2

公开(公告)日：2017-04-25

申请号：US14368102

申请日：2012-12-21

申请人： THE UNIVERSITY OF WESTERN ONTARIO

发明人： Chil-Yong Kang ,  Gyoung Nyoun Kim

IPC分类号： A61K39/205 ,  A61K39/00 ,  C07K14/145 ,  C12N7/04 ,  C07K14/005 ,  A61K39/12 ,  C12N7/00

CPC分类号： A61K39/39 ,  A61K39/12 ,  A61K39/205 ,  A61K39/21 ,  A61K39/29 ,  A61K2039/5252 ,  A61K2039/5254 ,  A61K2039/5256 ,  A61K2039/545 ,  A61K2039/55516 ,  A61K2039/57 ,  A61K2039/575 ,  C07K14/005 ,  C12N7/00 ,  C12N7/04 ,  C12N2740/16071 ,  C12N2740/16134 ,  C12N2740/16171 ,  C12N2740/16234 ,  C12N2740/16271 ,  C12N2740/16334 ,  C12N2760/20221 ,  C12N2760/20222 ,  C12N2760/20234 ,  C12N2760/20243 ,  C12N2760/20262 ,  C12N2760/20271 ,  C12N2770/24234 ,  C12N2770/24271

摘要： The present invention relates to vesicular stomatitis virus (VSV) matrix (M) protein mutants. One mutant M protein includes a glycine changed to a glutamic acid at position (21), a leucine changed to a phenylalanine at position (111) and a methionine changed to an arginine at position (51). Another M protein mutant includes a glycine changed to a glutamic acid at position (22) and a methionine changed to an arginine at positions (48) and (51). Yet another VSV M protein mutant includes a glycine changed to a glutamic acid at position (22), a leucine changed to a phenylalanine at position (110) and a methionine changed to an arginine at positions (48) and (51). The present invention is directed also to recombinant VSVs (rVSV) having these M mutants and to vaccines based on the rVSV having the M mutants of the present invention. These new rVSVs having the mutant M were significantly attenuated and lost virulence, including neurovirulence, and are capable of inducing an immune responses against an antigen of interest. In addition, a rVSV serotype Indiana having the first described M mutant is capable of efficient replication at 31° C., and of poor replication or incapable of replication at about 37° C. or higher.

公开(公告)号：US09623105B2

公开(公告)日：2017-04-18

申请号：US14977485

申请日：2015-12-21

申请人： Merial Inc.

发明人： Benjamin M. Hause

IPC分类号： A61K39/145 ,  A61K39/02 ,  A61K39/21 ,  A61K39/12 ,  C12N7/04 ,  C12N7/00 ,  A61K39/00

CPC分类号： A61K39/145 ,  A61K39/0241 ,  A61K39/12 ,  A61K39/21 ,  A61K2039/5252 ,  A61K2039/5254 ,  A61K2039/552 ,  C12N7/00 ,  C12N7/04 ,  C12N2760/16121 ,  C12N2760/16134 ,  C12N2760/16161

摘要： This disclosure provides attenuated swine influenza strains, particularly those produced via a reverse genetics approach, compositions comprising same, and methods of production and use thereof. The attenuated strains are engineered to encode HA proteins having additional glycosylation sites, relative to the HA proteins encoded by the corresponding virulent parental viruses. Advantageously, the attenuated influenza strains may be administered.

公开(公告)号：US20160296572A1

公开(公告)日：2016-10-13

申请号：US15037774

申请日：2014-11-24

申请人： YALE UNIVERSITY

发明人： Anthony N. Van Den Pol ,  Guido Wollmann

IPC分类号： A61K35/766 ,  A61K35/12 ,  A61K45/06 ,  A61K39/205 ,  C12N7/00 ,  A61K9/00

CPC分类号： A61K35/766 ,  A61K9/0019 ,  A61K9/0043 ,  A61K9/007 ,  A61K35/12 ,  A61K39/205 ,  A61K45/06 ,  A61K2039/5152 ,  A61K2039/5256 ,  C12N7/00 ,  C12N7/04 ,  C12N2760/20133 ,  C12N2760/20222 ,  C12N2760/20223 ,  C12N2760/20232 ,  C12N2760/20234

摘要： Methods of treating cancer including administering to a subject with cancer a pharmaceutical composition including an effective amount of a chimeric VSV virus are disclosed. The chimeric viruses are based on a VSV background where the VSV G protein is replaced with one or more heterologous viral glycoproteins. In the most preferred embodiment, the VSV G protein is replaced with the glycoprotein from Lassa virus or a functional fragment thereof. The resulting chimeric virus is an oncolytic virus that is attenuated and safe in the brain, yet still retains sufficient oncolytic activity to infect and destroy cancer cells such glioblastoma, and to generate an immune response against infected cancer cells. Methods of using chimeric viruses as a platform for immunization against other pathogenic microbes are also provided.

摘要翻译： 公开了治疗癌症的方法，包括向受试者施用包含有效量的嵌合VSV病毒的药物组合物。 嵌合病毒基于VSV背景，其中VSV G蛋白被一种或多种异源病毒糖蛋白替代。 在最优选的实施方案中，VSV G蛋白被来自Lassa病毒的糖蛋白或其功能片段替代。 所得到的嵌合病毒是在脑中减毒和安全的溶瘤病毒，但仍保留足够的溶瘤活性以感染和破坏癌细胞如胶质母细胞瘤，并产生针对感染的癌细胞的免疫应答。 还提供了使用嵌合病毒作为免疫其他致病微生物的平台的方法。

公开(公告)号：US20160279232A1

公开(公告)日：2016-09-29

申请号：US15054404

申请日：2016-02-26

申请人： Pulike Biological Engineering, Inc.

发明人： Kegong TIAN ,  Xuke ZHANG ,  Jinzhong SUN ,  Feifei TAN

IPC分类号： A61K39/245 ,  C12N7/00

CPC分类号： A61K39/245 ,  A61K39/12 ,  A61K45/06 ,  A61K2039/5252 ,  A61K2039/5254 ,  A61K2039/543 ,  A61K2039/545 ,  A61K2039/552 ,  C12N7/00 ,  C12N7/04 ,  C12N2710/16011 ,  C12N2710/16634 ,  C12N2710/16721 ,  C12N2710/16734 ,  C12N2710/16762 ,  C12N2710/16771 ,  C12N2770/20071

摘要： The present invention provides an attenuated strain of porcine pseudorabies virus (PRV), in which said attenuated strain of PRV is a variant strain of PRV with inactivation of gI/gE/11K/28K proteins. In addition, the present invention also provides a vaccine composition comprising the attenuated strain of PRV as an antigen, a preparation method and use thereof. Proved by immunogenicity and pathogenicity testing of the live vaccine, said live PRV vaccine can provide a good protection for pigs with no clinical signs observed, indicating excellent immune protection.

摘要翻译： 本发明提供了猪伪狂犬病毒（PRV）的减毒菌株，其中所述减毒株PRV是具有gI / gE / 11K / 28K蛋白质失活的PRV的变体菌株。 此外，本发明还提供包含PRV的减毒菌株作为抗原的疫苗组合物，其制备方法和用途。 通过活疫苗的免疫原性和致病性检测证实，活疫苗疫苗可以为猪提供良好的保护，没有观察到临床症状，表明优良的免疫保护。